Barinthus Biotherapeutics (BRNS) EBIT Margin (2020 - 2024)

Barinthus Biotherapeutics' (BRNS) quarterly EBIT Margin came in at 62.66% in Q3 2024, up 99.21% on a QoQ basis from 7885.33% in Q2 2023.

Barinthus Biotherapeutics (BRNS) EBIT Margin (2020 - 2024) Analysis & Trends

Barinthus Biotherapeutics (BRNS) has 5 years of EBIT Margin data on file, last reported at 62.66% in Q3 2024.

Quarterly EBIT Margin changed N/A year-over-year to 62.66% in Q3 2024, while the trailing twelve-month figure through Dec 2025 was 471.34% (down 1727.0% YoY) and the FY2024 annual result came in at 454.07%, up 1000902.0% from the prior year.
EBIT Margin advanced to 62.66% in Q3 2024, from 7885.33% in the prior quarter.
In the past five years, EBIT Margin ranged from a high of 1666800.0% in Q4 2021 to a low of 48128.57% in Q2 2021.
A 5-year average of 104644.19% and a median of 659.43% in 2020 frame the typical range for EBIT Margin.
Annual changes were most pronounced in 2021 — EBIT Margin surged 166952119 bps — and 2022, when it tumbled 166718862 bps.
Tracing BRNS's EBIT Margin over 5 years: stood at 2721.19% in 2020, then soared by 61353 bps to 1666800.0% in 2021, then plunged by 100 bps to 388.62% in 2022, then tumbled by 1929 bps to 7885.33% in 2023, then surged by 99 bps to 62.66% in 2024.
The last three EBIT Margin figures came in at 62.66% (Q3 2024), 7885.33% (Q2 2023), and 4590.6% (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Barinthus Biotherapeutics	25.01 Mn	25.01 Mn	-	-

Download Data